/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Moleculin Biotech, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$7.5 0.1448(14.48%) MBRX at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 6.79
Highest Today 7.59
Today’s Open 6.79
Prev. Close 6.63
52 Week High 77.50
52 Week Low 6.01
Day’s Range: Low 6.79 High 7.59
52-Week Range: Low 6.01 High 77.50
1 day return -
1 Week return +12.48
1 month return +1415.81
3 month return +1904.76
6 month return +1034.08
1 year return +196.86
3 year return -60.26
5 year return -90.11
10 year return -

Institutional Holdings

Vanguard Institutional Extnd Mkt Idx Tr 0.29

Citigroup Inc 0.28

XTX Topco Ltd 0.25

Fidelity Extended Market Index 0.22

Virtu Financial LLC 0.20

LPL Financial Corp 0.19

VERUS CAPITAL PARTNERS, LLC 0.14

Vanguard Group Inc 0.10

Geode Capital Management, LLC 0.09

Fidelity Series Total Market Index 0.07

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.04

BlackRock Inc 0.04

BB&T Corp. 0.03

Spartan Total Market Index Pool G 0.03

UBS Group AG 0.03

Tower Research Capital LLC 0.01

Stone House Investment Management, LLC 0.01

Newbridge Financial Services Group, Inc. 0.01

Fidelity Total Market Index 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Morgan Stanley - Brokerage Accounts 0.00

State St US Extended Mkt Indx NL Cl C 0.00

SBI Securities Co Ltd 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Spartan Extended Market Index Pool F 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Atlantic Union Bankshares Corp 0.00

Barclays PLC 0.00

SSgA U.S. Total Market Index Strategy 0.00

Bogart Wealth, LLC 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Bank of America Corp 0.00

Northern Trust Wilshire 5000 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Market Status

Strong Buy: 0

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 22.47 M

PB Ratio 476.1996

PE Ratio 0.0

Enterprise Value 340.77 M

Total Assets 16.93 M

Volume 165373

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-164000 -0.2M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-26270000 -26.3M, FY22:-27410000 -27.4M, FY21:-8860000 -8.9M, FY20:-14996000 -15.0M, FY19:-13205000 -13.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:63000 0.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-21000 -0.0M, Q2/2025:-29000 -0.0M, Q1/2025:-31000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-31000 -0.0M

Quarterly Net worth Q3/2025:-25399000 -25.4M, Q2/2025:-7640000 -7.6M, Q1/2025:-6436000 -6.4M, Q3/2024:-10592000 -10.6M, Q2/2024:-4319000 -4.3M

Fund house & investment objective

Company Information Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. Walter V. Klemp

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow